Drug Trial Radar · NCT04333914
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection
Last checked: Nov 19, 2026Latest source record: Sep 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Apr 15, 2020
Primary completion
Jul 6, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Centre Leon BerardAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, controlled, randomized, multicenter study whose goal is to compare the efficacy of an autophagy inhibitor (GNS561), an anti-NKG2A (monalizumab) and an anti-C5aR (avdoralimab) versus standard of care in patients with advanced or metastatic cancer who have Sars-CoV-2 infection not eligible to a resuscitation unit. According to their severity level at the time of enrolment, eligible patients will be randomized into 2 different cohorts: * COHORT 1 (mild symptoms or asymptomatic): GNS561 vs anti-NKG2A vs standard of care (randomization ratio 1:1:1). * COHORT 2 (moderate/severe symptoms): anti-C5aR vs standard of care (randomization ratio 1:1).
Conditions
- SARS-CoV-2 (COVID-19) Infection
- Advanced or Metastatic Hematological or Solid Tumor
Interventions
Autophagy inhibitor (GNS651)Drug
Cohort 1 (arm B): 200mg q.d. orally for 10 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.
Standard of careOther
In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation. Additional care and medications should be administered in the patient's best interest.
AvdoralimabDrug
Cohorte 2 (arm H): 500mg, intravenously, at Day 1 then 200mg once daily every 2 days during 14 Days
MonalizumabDrug
Cohorte 2 (arm G) : 50mg (flat dose),intravenously, single infusion at Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 28-day survival rateTime frame: 28 days from randomization
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Centre Jean Perrin
Clermont-Ferrand, France
CHU Clermont Ferrand
Clermont-Ferrand, France
Centre Oscar Lambret
Lille, France
AP-HP Hôpital Saint Antoine
Paris, France
AP-HP La Pitié Salpétrière
Paris, France
Hôpital Saint-Joseph
Paris, France
AP-HP Tenon
Paris, France
AP-HP Hôpital Bichat Claude Bernard
Paris, France
GH Diaconesses Croix Saint Simon
Paris, France
Institut de cancérologie Strasbourg Europe (ICANS)
Strasbourg, France
Institut Gustave Roussy
Villejuif, France
Centre Léon Bérard
Lyon, Rhône, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.